Gentamicin and renal function: Lessons from 15 years experience of a pharmacokinetic service for extended interval dosing of gentamicin

Therapeutic Drug Monitoring

Volumn 37, Issue 1, 2015, Pages 98-103

  Plajer, Sabine M ^a,b   Chin, Paul K L ^a   Vella Brincat, Jane W A ^a   Buffery, Pamela J ^a   Begg, Evan J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Apotek 1 Mediegarden   (Norway)

Author keywords

Aminoglycosides; dose interval; extended interval dosing; nephrotoxicity

Indexed keywords

CREATININE; GENTAMICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG HALF LIFE; EXTENDED INTERVAL DOSING; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEPSIS;

EID: 84963941054     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000107     Document Type: Article

References (18)

1. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995;39:605-609.
2. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93-99.
3. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a oncedaily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650-655.
4. Barclay ML, Begg EJ. Aminoglycoside adaptive resistance: importance for effective dosage regimens. Drugs. 2001;61:713-721.
5. Barclay ML, Kirkpatrick CMJ, Begg EJ. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet. 1999;36:89-98.
6. Oliveira JFP, Silva CA, Barbieri CD, et al. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009;53:2887-2891.
7. Spanggaard MH, Honge BL, Schonheyder HC, et al. Short term gentamicin therapy and risk of renal toxicity in patients with bacteraemia. Scand J Infect Dis. 2011;43:953-956.
8. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984;100: 352-357.
9. Thummel KE, Shen DD, Isoherranen N. Design and optimization of dosage regimens: pharmacokinetic data. In: Brunton LL, ed. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011:1891-1990.
10. Begg EJ, Vella-Brincat JWA, Borrie TL, Takawira C, Chin PKL. Preferred Medicines List. 16th ed. Christchurch, New Zealand: The Caxton Press; 2012.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
12. Kirkpatrick CM, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol. 1999;47:637-643.
13. Duffull SB, Kirkpatrick CM, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol. 1997;43:125-135.
14. Benet LZ, Oie S, Schwartz JB. Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:1707-1792.
15. Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79:33-45.
16. Pogue JM, Potoski BA, Kaye KS. Aminoglycoside use in intensive care units and aminoglycoside toxicity. Antimicrob Agents Chemother. 2010; 54:2750-2751.
17. Chin PKL, Florkowski CM, Begg EJ. The performances of the Cockcroft-Gault, modification of diet in renal disease study and chronic kidney disease epidemiology collaboration equations in predicting gentamicin clearance. Ann Clin Biochem. 2013;50:546-557.
18. Demczar DJ, Nafziger AN, Bertino JS. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once daily aminoglycoside dosing. Antimicrob Agents Chemother. 1997;41:1115-1119.